Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Researchers have uncovered a compelling potential link between a chronic gut infection caused by a common virus and the ...

Recent advances in molecular biology have provided unprecedented insights into the structure of amyloid fibrils associated ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

The litany of failed trials of amyloid-targeting drugs for Alzheimer's disease has added another verse, as Roche concedes that its crenezumab candidate was unable to slow cognitive decline in ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Mild traumatic brain injury leads to reactivation of herpes simplex virus type 1, which may promote neurodegeneration and ...

Research reveals how herpes simplex virus-1 may contribute to Alzheimer’s disease, offering new insights into the disease’s ...

Eplontersen sodium is under clinical development by AstraZeneca and currently in Phase III for Familial Amyloid Cardiomyopathy.